Copyright © 1996, 1997, 2001 by Galen Daryl Knight
and VitaleTherapeutics, Inc.
Niacin Analogues
Tobacco products are considered to be predisposing factors in several forms
of cancer. According to the American Cancer
Society, there are 43 carcinogenic substances in tobacco smoke, and
nicotine makes the use of tobacco products addictive. Smokeless tobacco
(plug or leaf chewable tobacco or snuff) is considered to be a predisposing
factor in oral cancers (US Surgeon General, 1986). Cadmium and nickel also
have been inplicated in the carcinogenicity of tobacco products.
Since removal of tar by filters and the use of smokeless tobacco do
not eliminate the risk of cancer associated with tobacco, the question
remains "What are the components of tobacco most responsible for the increased
risks of cancer?" One obvious possibility from our perspective is nicotine,
itself, for its potential to interfere with monooxygenase-catalyzed
reactions in about five ways:
There is no question that metabolites of nicotine are carcinogenic and
that nicotine itself is a cancer promoter in laboratory animals. Some
human lung cancer cells that normally double every three days in cell
culture will nearly triple over this same time period if nicotine is included
in the medium. Though a gross oversimplification, it is an ironic coincidence
that the maximum velocity for nicotine is a little less than two-thirds
that of other substrates for the monooxygenase (supra) and that the growth
rate of some cancer cells is three-halves as fast when nicotine is present
in the culture medium. Let's see if linking observations by four different
researchers about nicotine
and carcinogenesis and the monooxygenase lends
substance to this assertion and, at the same time, drives a message home:
-
Nicotine, the addictive substance in tobacco products (even the pinch-between-the-cheek-and-gum,
smokeless kind), promotes tumor induction
with DMBA in the cheek pouch of hamsters; nicotine cause the numbers
of small tumors produced by DMBA to more than triple, the numbers of medium-sized
tumors to more than double, and even greater increases in numbers of large
tumors.
-
An endogenous substrate for the monooxygenase, cysteamine,
protects against the carcinogenesis with DMBA, possibly by sacrificial
protection of the vitaletheine modulators.
-
Substrates for the monooxygenase that
do not resemble the vitaletheine modulators are often carcinogenic; cysteamine
is part of the base structure for the vitaletheine modulators.
-
In addition to being carcinogenic, DMBA nearly
eliminates the hemolytic plaque response; the numbers of immune cells
that can produce protective cytolytic antibodies when challenged are diminished
95% or more by DMBA.
-
Vitalethine stimulates the production
of protective cytolytic antibodies, treats cancer, and is suspected of
being an endogenous substrate for the monooxygenase.
-
A survey of the literature indicates that
the hemolytic plaque response is often linked inversely to carcinogenesis,
especially when the investigative agent affecting the antibody producing
cells is not overtly cytotoxic toward and does not directly affect the
proliferation of immune or tumor cells; under these circumstances, agents
that stimulate the plaque-forming (cytolytic antibody) response typically
protect against cancer, whereas those that inhibit the production of these
cytolytic antibodies (like the agents, DMBA and MMI) promote the development
of tumors. It is interesting that MMI is a conjugated thiol and one of
the best substrates for the monooxygenase, but this is where the similarities
with cysteamine and the vitaletheine modulators end; MMI uncouples hemolytic
plaque responses and other important biological processes (such as the
production of thyroid hormone), whereas cysteamine
and other metabolites in the Coenzyme A pathway
increase iodide incorporation and stimulate immunological responses.
An interesting general feature about the regulation of biological systems
is that minor inhibition at any one step in a regulatory cascade (10% here,
10% there) can be amplified by multiple affected sites along the entire
pathway to produce dramatic inhibition at the endpoint. The potential for
cascade-amplified inhibition of the monooxygenase with nicotine clearly
exists. If nicotine proves to be a predisposing factor through this proposed
mechanism, nicotine patches will solve a tobacco consumer's risk for cancer
only if used to completely end the addiction.
GO TO: